Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 4Phase 3 2

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4Thoracic 1Head & Neck 1Gynecologic 1

Conditions

Melanoma 4Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Nivolumab 114Ipilimumab 114pembrolizumab 108aldesleukin 76Cyclophosphamide 70fludarabine phosphate 51Interleukin-2 48Temozolomide 41Dacarbazine 36trametinib 33dabrafenib 30Bevacizumab 30sargramostim 29Radiotherapy 29incomplete Freund's adjuvant 27fludarabine 27Vemurafenib 25Radiosurgery 25Carboplatin 25Paclitaxel 23binimetinib 22Biopsy 22CTLA-4 Antigen 21Peripheral Blood Stem Cell Transplantation 20encorafenib 19cemiplimab 19atezolizumab 19HhAntag691 19Mycophenolic Acid 18Aminolevulinic Acid 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × lifileucel × Dermatologic × Clear all
NCT03645928 2026-05-15

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Iovance Biotherapeutics, Inc.

Phase 2 Terminated
225 enrolled
DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT06151847 2026-04-30

Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma

University of Kansas Medical Center

Phase 2 Completed
11 enrolled
Dermatologic

Melanoma

NCT07288203 2026-04-20

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma

Iovance Biotherapeutics, Inc.

Phase 2 Active not recruiting
100 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT02360579 2026-03-25

LN-144

Iovance Biotherapeutics, Inc.

Phase 2 Completed
220 enrolled 16 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡